Benign Inclusion of Axillary Lymph Nodes: Report of Two Cases and Literature Review

Department of Pathology, University of Rochester Medical Center, Rochester, New York, USA.
The Breast Journal (Impact Factor: 1.41). 09/2009; 15(6):664-5. DOI: 10.1111/j.1524-4741.2009.00815.x
Source: PubMed
Download full-text


Available from: David G Hicks, Jan 04, 2016
  • [Show abstract] [Hide abstract]
    ABSTRACT: The occurrence of various types of heterotopic epithelial structures in lymph nodes is a well-documented phenomenon. Here, we report on the presence of such inclusions in axillary lymph nodes. A total of 18 cases were identified. All patients were women, their ages ranging from 32 to 79 years (median, 57 y). Thirteen patients had concomitant or antecedent breast abnormalities, and 12 of them had undergone nodal sampling for staging purposes. The other 5 patients had noted enlarging axillary masses, with no clinical evidence of previous or concomitant breast or genital tract pathology. We classified the nodal inclusions on morphologic grounds into 3 main categories: those composed exclusively of glandular structures (glandular-type inclusions; 10 cases, 56%); those made up only of squamous cysts (squamous-type inclusions; 2 cases, 11%); and those containing both glandular and squamous epithelia (mixed glandular-squamous-type inclusions; 6 cases, 33%). We speculate about the possible mechanism for the migration of the epithelial cells into the lymph nodes, discuss the modifications that they may later undergo as a result of local and systemic factors, and consider the differential diagnosis with other conditions, particularly with metastatic well-differentiated breast carcinoma.
    No preview · Article · Aug 2011 · The American journal of surgical pathology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Most diagnoses in breast pathology can be rendered after careful evaluation of a high quality hematoxylin and eosin-stained tissue section. However, a significant number of both benign and malignant lesions can show variable morphologic patterns and significant histologic overlap, leading to diagnostic uncertainty. These challenges and complexities have opened the door to an expanding role for immunohistochemistry (IHC) as an important diagnostic adjunct for solving frequently encountered problems in breast pathology. Although IHC has proven to be a powerful tool in helping to resolve difficult cases, the results of such studies should always be carefully interpreted within the morphologic context for each lesion. This article will briefly review some of the more common circumstances in which IHC has been shown to be useful in diagnostic breast pathology.
    Full-text · Article · Dec 2011 · Applied immunohistochemistry & molecular morphology: AIMM / official publication of the Society for Applied Immunohistochemistry
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although there have been several studies on the use of immunohistochemical biomarkers of canine mammary tumors (CMTs), the results are difficult to compare. This article provides guidelines on the most useful immunohistochemical markers to standardize their use and understand how outcomes are measured, thus ensuring reproducibility of results. We have reviewed the biomarkers of canine mammary epithelial and myoepithelial cells and identified those biomarkers that are most useful and those biomarkers for invasion and lymph node micrometastatic disease. A 10% threshold for positive reaction for most of these markers is recommended. Guidelines on immunolabeling for HER2, estrogen receptors (ERs), and progesterone receptors (PRs) are provided along with the specific recommendations for interpretation of the results for each of these biomarkers in CMTs. Only 3+ HER2-positive tumors should be considered positive, as found in human breast cancer. The lack of any known response to adjuvant endocrine therapy of ER- and PR-positive CMTs prevents the use of the biological positive/negative threshold used in human breast cancer. Immunohistochemistry results of ER and PR in CMTs should be reported as the sum of the percentage of positive cells and the intensity of immunolabeling (Allred score). Incorporation of these recommendations in future studies, either prospective or retrospective, will provide a mechanism for the direct comparison of studies and will help to determine whether these biomarkers have prognostic significance. Finally, these biomarkers may ascertain the most appropriate treatment(s) for canine malignant mammary neoplasms.
    Full-text · Article · Nov 2013 · Veterinary Pathology
Show more